Iron and Obesity Status-Associated Insulin Resistance Influence Circulating Fibroblast-Growth Factor-23 Concentrations

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Fernández Real, José Manuel ^a   Puig, Josep ^a   Serrano, Marta ^a   Sabater, Mónica ^a   Rubió, Antoni ^a   Moreno Navarrete, José María ^a   Fontan, Marina ^a   Casamitjana, Roser ^b   Xifra, Gemma ^a   Ortega, Francisco José ^a   Salvador, Javier ^c   Frühbeck, Gema ^c   Ricart, Wifredo ^a  

^a Instituto de Salud Carlos III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; IRON; PARATHYROID HORMONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BONE DENSITY; CARBOXY TERMINAL SEQUENCE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT MASS; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; SEX DIFFERENCE; WEIGHT REDUCTION;

ADULT; BLOOD VESSELS; FERRITINS; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; IRON; MALE; MIDDLE AGED; OBESITY; WEIGHT LOSS;

EID: 84875315066     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058961     Document Type: Article

References (33)

1. Fukumoto S, Martin TJ, (2009) Bone as an endocrine organ. Trends Endocrinol Metab 20: 230-6.
2. Yamashita T, Yoshioka M, Itoh N, (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277: 494-498.
3. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505.
4. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, et al. (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112: 683-692.
5. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, et al. (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315.
6. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, et al. (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49.
7. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, et al. (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 1656-1663.
8. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960.
9. Ferrari SL, Bonjour JP, Rizzoli R, (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524.
10. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592.
11. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796.
12. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, et al. (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul study. Ann Intern Med 152: 640-648.
13. Mirza MA, Larsson A, Lind L, Larsson TE, (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385-390.
14. Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, et al. (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24: 3125-3131.
15. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE, (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551.
16. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, et al. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552.
17. Hsu HJ, Wu MS, (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337: 116-122.
18. Mirza MA, Alsiö J, Hammarstedt A, Erben RG, Michaëlsson K, et al. (2011) Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 31: 219-27.
19. Bergman RN, Prager R, Volund A, Olefsky JM, (1987) Equivalence of the insulin sensitivity index in man derived by the minimal model method and euglycaemic glucose clamp. J Clin Invest 79: 790-800.
20. Sabater M, Moreno-Navarrete JM, Ortega FJ, Pardo G, Salvador J, et al. (2010) Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab 95: 4720-8.
21. World Health Organization Study Group on Assessment of Fracture Risk and Its Application to Screening and Postmenopausal Osteoporosis (1994) Report of a WHO Study Group. Technical Report Series(No. 84).
22. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, et al. (2007) Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 23: 75-80.
23. Durham BH, Joseph F, Bailey LM, Fraser WD, (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 44: 463-466.
24. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, et al. (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A 107: 407-12.
25. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, et al. (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108: E1146-E1155.
26. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, et al. (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96: 3541-3549.
27. Marsell R, Mirza MA, Mallmin H, Karlsson M, Mellström D, et al. (2009) Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 20: 1167-73.
28. Gutiérrez OM, Wolf M, Taylor EN, (2011) Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 6: 2871-8.
29. Holecki M, Chudek J, Wie{ogonek}cek A, Titz-Bober M, Duława J, (2011) The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. Int J Endocrinol 2011: 707126.
30. Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, et al. (2012) Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 97: 1655-62.
31. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N, (2010) Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 25: 1711-23.
32. Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, et al. (2012) FGF23 contributes to insulin sensitivity in obese adolescents - preliminary results. Clin Endocrinol (Oxf) 77: 537-40.
33. Winther K, Nybo M, Vind B, Pedersen SM, Højlund K, et al. (2011) Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients. Scand J Clin Lab Invest 72: 108-13.